# Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

> **NCT04464122** · — · RECRUITING · sponsor: **University of Roma La Sapienza** · enrollment: 60 (estimated)

## Conditions studied

- Neuroendocrine Tumors
- Neuroendocrine Neoplasm
- Neuroendocrine Tumor Grade 1
- Neuroendocrine Tumor Grade 2
- Neuroendocrine Carcinoma

## Interventions

- **DRUG:** Somatostatin analog; chemotherapy

## Key facts

- **NCT ID:** NCT04464122
- **Lead sponsor:** University of Roma La Sapienza
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-14
- **Primary completion:** 2025-09-14
- **Final completion:** 2025-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04464122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04464122, "Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04464122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*